The reported pharmacokinetic study suggested that CYP2E1 was the most stable enzyme, whereas CYP2C19 (with CYP1A1 and CYP2D6 in the middle) was the most vulnerable in liver failure [1]. This evidence concerns the gene CYP2C19 and Hepatic failure.